SCHEMBL936809

SCHEMBL936809

Cc1ccc(OS(=O)(=O)Oc2ccc(C)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.67
CA9 Q16790 4/20 0.67
CA1 P00915 3/20 0.67
PPARG P37231 1/20 0.48
ACHE P22303 2/20 0.48
CYP3A4 P08684 1/20 0.46
TSHR P16473 1/20 0.46
GAA P10253 2/20 0.46
HTT P42858 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 1/20 0.44
CA12 O43570 1/20 0.42
CA3 P07451 1/20 0.42
CA6 P23280 1/20 0.42
CA5A P35218 1/20 0.42
CA7 P43166 1/20 0.42
CA5B Q9Y2D0 1/20 0.42
TDP1 Q9NUW8 3/20 0.42
TLR9 Q9NR96 1/20 0.41
TEAD4 Q15561 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3887581 0.91 HTT (0.58) CA2CA9CA1PPARGACHE
SCHEMBL3884706 0.88 CA2 (0.59) CA2CA9CA1PPARGACHE
SCHEMBL3363890 0.87 CA2 (0.53) CA2CA9CA1PPARGACHE
SCHEMBL20017110 0.86 CA2 (0.57) CA2CA9CA1PPARGACHE
SCHEMBL27604161 0.84 CA2 (0.55) CA2CA9CA1PPARGACHE
SCHEMBL17466421 0.83 CA2 (0.53) CA2CA9CA1PPARGACHE
SCHEMBL3895027 0.83 CA2 (0.53) CA2CA9CA1PPARGACHE
SCHEMBL17466353 0.83 CA2 (0.53) CA2CA9CA1PPARGACHE
SCHEMBL28224975 0.82 CA1 (0.48) CA2CA9CA1PPARGGAA
SCHEMBL168170 0.82 CA2 (0.64) CA2CA9CA1PPARGACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2302030-B1 Reagents for lysis of bacterial cells ROCHE DIAGNOSTICS GMBH (DE) 2011-11-16 EP claimed
EP-0465730-B1 Photographic infrared sensitized material containing a speed enhancing agent AGFA GEVAERT NV (BE) 1996-06-05 EP claimed
WO-1995020637-A2 HYDROCARBON OIL-AQUEOUS FUEL AND ADDITIVE COMPOSITIONS MEG S.N.C. DI SCOPELLITI SOFIA & C. (IT) 1995-08-03 WO claimed
EP-0465730-A1 Photographic infrared sensitized material containing a speed enhancing agent AGFA-GEVAERT N.V. (BE) 1992-01-15 EP claimed
US-12100809-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-24 US disclosed
CN-110088108-B Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors 联合疗法公司 2024-06-14 CN disclosed
US-20230364093-A1 PHARMACEUTICAL COMPOSITION CONTAINING PALBOCICLIB AND LETROZOLE EGIS GYÓGYSZERGYÁR ZRT. (HU) 2023-11-16 US disclosed
US-11672804-B1 Pharmaceutical composition containing palbociclib and letrozole EGIS GYÓGYSZERGYÁR ZRT. (HU) 2023-06-13 US disclosed
US-20220149436-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2022-05-12 US disclosed
US-11283107-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2022-03-22 US disclosed
CN-112007052-A Kidney-protecting probiotic composition 上海泓商生物科技有限公司 2020-12-01 CN disclosed
CN-111032064-A Methods for maintaining and improving renal function in patients with renal disease and receiving standard of care therapy 基博生物技术公司 2020-04-17 CN disclosed
US-20030219673-A1 Selected acid generating agents and their use in processes for imaging radiation-sensitive elements FPC INC. 2003-11-27 US disclosed
EP-0465730-B1 Photographic infrared sensitized material containing a speed enhancing agent AGFA GEVAERT NV (BE) 1996-06-05 EP disclosed
WO-1995020637-A2 HYDROCARBON OIL-AQUEOUS FUEL AND ADDITIVE COMPOSITIONS MEG S.N.C. DI SCOPELLITI SOFIA & C. (IT) 1995-08-03 WO disclosed
EP-0609571-A1 Stilbene compounds as supersensitizers in infrared sensitive photographic materials AGFA-GEVAERT N.V. (BE) 1994-08-10 EP disclosed
US-5190854-A Cyanine sensitizers and quinolone compounds AGFA-GEVAERT, N.V. (BE) 1993-03-02 US disclosed
US-5190854-A Cyanine sensitizers and quinolone compounds AGFA-GEVAERT, N.V. (BE) 1993-03-02 US disclosed
EP-0465730-A1 Photographic infrared sensitized material containing a speed enhancing agent AGFA-GEVAERT N.V. (BE) 1992-01-15 EP disclosed
EP-0465730-A1 Photographic infrared sensitized material containing a speed enhancing agent AGFA-GEVAERT N.V. (BE) 1992-01-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11672804-B1 Pharmaceutical composition containing palbociclib and letrozole CDK4, BRCA1, CDK11B CA2 3723/4885CA9 1906/4885CA1 4521/4885
US-20230364093-A1 PHARMACEUTICAL COMPOSITION CONTAINING PALBOCICLIB AND LETROZOLE CDK4, BRCA1, CDK11B CA2 3723/4885CA9 1906/4885CA1 4521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.